First Sponsored Contact Lens Recycling Program Collects More Than 7,000 lbs. of Waste
LAVAL, Quebec, Nov. 15, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX andTSX: VRX) wholly owned subsidiary, Bausch + Lomb, today announced that its unique ONE by ONE Recycling Program has recycled a combined total of more than one million used contact lenses, blister packs and top foils in less than one year since its launch. Made possible through a collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste, the ONE by ONE Recycling Program has diverted more than 7,000 pounds of waste from landfills.
In addition, for every pound of accepted packaging received through this program, a $1 donation is made to Optometry Giving Sight, the only global fundraising initiative that specifically targets the prevention of blindness and impaired vision by providing eye exams and glasses to those in need.
"We are globally committed to environmental sustainability while also delivering innovations that meet the needs of our physicians and their patients," said Joseph C. Papa, chairman and CEO, Valeant. "We are proud of the ONE by ONE Recycling Program, which has made significant strides in its first year by helping to reduce contact lens waste as well as helping to provide basic vision care to those who are in need."
Although contact lenses and their packaging are generally composed of recyclable plastic or foil, they often end up being filtered out of most standard recycling centers due to their small size. Currently, the end-to-end trail of waste generated from contact lens packaging annually in the United States could circle the earth three times. The ONE by ONE Recycling Program provides contact lens wearers the opportunity to properly recycle their used materials and reduce the amount of waste deposited to landfills across the country.
To participate in the program, contact lens wearers can print a free ONE by ONE shipping label and ship their used blister packs, top foil and contact lenses via any UPS location or drop off their waste at a participating eye doctor's office. All participating offices in the United States (more than 2,000 to date) can be found on the program's website, www.bauschrecycles.com.
About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Our core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.
SOURCE Valeant Pharmaceuticals International, Inc.